MANABU EMI

Last Updated :2024/02/01

Affiliations, Positions
Research Institute for Radiation Biology and Medicine, Assistant Professor
E-mail
emirinhiroshima-u.ac.jp
Self-introduction
Conducting clinical and research on esophageal cancer treatment at Hiroshima University Hospital.

Basic Information

Academic Degrees

  • Hiroshima University

Educational Activity

Course in Charge

  1. 2023, Undergraduate Education, Intensive, Introduction to clinical clerkship
  2. 2023, Undergraduate Education, Intensive, Practice for medical research
  3. 2023, Undergraduate Education, Intensive, Practice of Medicine I
  4. 2023, Undergraduate Education, Intensive, Practice of Medicine II
  5. 2023, Undergraduate Education, First Semester, Surgery I

Research Activities

Academic Papers

  1. Successful management of multiple esophagorespiratory fistulas using two types of stent: Report of a case, SURGERY TODAY, 41(4), 560-562, 2011
  2. Esophageal reconstruction using the terminal ileum and right colon in esophageal cancer surgery, SURGERY TODAY, 42(4), 342-350, 2012
  3. Esophageal reconstruction using the terminal ileum and right colon in esophageal cancer surgery, SURGERY TODAY, 42(4), 342-350, 2012
  4. Esophageal reconstruction using the terminal ileum and right colon in esophageal cancer surgery, SURGERY TODAY, 42(4), 342-350, 2012
  5. Airway Stenting for Malignant Respiratory Complications in Esophageal Cancer, ANTICANCER RESEARCH, 32(5), 1785-1790, 2012
  6. Airway Stenting for Malignant Respiratory Complications in Esophageal Cancer, ANTICANCER RESEARCH, 32(5), 1785-1790, 2012
  7. Airway Stenting for Malignant Respiratory Complications in Esophageal Cancer, ANTICANCER RESEARCH, 32(5), 1785-1790, 2012
  8. Advanced esophageal cancer with an esophago-bronchial fistula successfully treated by chemoradiotherapy following esophageal bypass surgery: report of a case, SURGERY TODAY, 42(11), 1088-1090, 2012
  9. Advanced esophageal cancer with an esophago-bronchial fistula successfully treated by chemoradiotherapy following esophageal bypass surgery: report of a case, SURGERY TODAY, 42(11), 1088-1090, 2012
  10. Advanced esophageal cancer with an esophago-bronchial fistula successfully treated by chemoradiotherapy following esophageal bypass surgery: report of a case, SURGERY TODAY, 42(11), 1088-1090, 2012
  11. Involvement of ribonucleotide reductase-M1 in 5-fluorouracil-induced DNA damage in esophageal cancer cell lines, INTERNATIONAL JOURNAL OF ONCOLOGY, 42(6), 1951-1960, 2013
  12. Involvement of ribonucleotide reductase-M1 in 5-fluorouracil-induced DNA damage in esophageal cancer cell lines, INTERNATIONAL JOURNAL OF ONCOLOGY, 42(6), 1951-1960, 2013
  13. Involvement of ribonucleotide reductase-M1 in 5-fluorouracil-induced DNA damage in esophageal cancer cell lines, INTERNATIONAL JOURNAL OF ONCOLOGY, 42(6), 1951-1960, 2013
  14. Treatment Outcomes and Prognostic Factors for Thoracic Esophageal Cancer with Clinical Evidence of Adjacent Organ Invasion, ANTICANCER RESEARCH, 33(8), 3495-3502, 2013
  15. Treatment Outcomes and Prognostic Factors for Thoracic Esophageal Cancer with Clinical Evidence of Adjacent Organ Invasion, ANTICANCER RESEARCH, 33(8), 3495-3502, 2013
  16. Treatment Outcomes and Prognostic Factors for Thoracic Esophageal Cancer with Clinical Evidence of Adjacent Organ Invasion, ANTICANCER RESEARCH, 33(8), 3495-3502, 2013
  17. Involvement of homologous recombination in the synergism between cisplatin and poly (ADP-ribose) polymerase inhibition, CANCER SCIENCE, 104(12), 1593-1599, 2013
  18. Involvement of homologous recombination in the synergism between cisplatin and poly (ADP-ribose) polymerase inhibition, CANCER SCIENCE, 104(12), 1593-1599, 2013
  19. Involvement of homologous recombination in the synergism between cisplatin and poly (ADP-ribose) polymerase inhibition, CANCER SCIENCE, 104(12), 1593-1599, 2013
  20. Esophageal reconstruction using the terminal ileum and right colon in esophageal cancer surgery, 42(4), 342-350, 20120401
  21. Esophageal reconstruction using the terminal ileum and right colon in esophageal cancer surgery, 42(4), 342-350, 20120401
  22. Esophageal reconstruction using the terminal ileum and right colon in esophageal cancer surgery, 42(4), 342-350, 20120401
  23. Advanced esophageal cancer with an esophago-bronchial fistula successfully treated by chemoradiotherapy following esophageal bypass surgery : report of a case, 42(11), 1088-1090, 20121101
  24. Advanced esophageal cancer with an esophago-bronchial fistula successfully treated by chemoradiotherapy following esophageal bypass surgery : report of a case, 42(11), 1088-1090, 20121101
  25. Advanced esophageal cancer with an esophago-bronchial fistula successfully treated by chemoradiotherapy following esophageal bypass surgery : report of a case, 42(11), 1088-1090, 20121101
  26. Current status of the molecular mechanisms of anticancer drug-induced apoptosis. The contribution of molecular-level analysis to cancer chemotherapy., Cancer chemotherapy and pharmacology, 50(5), 2002
  27. Current status of the molecular mechanisms of anticancer drug-induced apoptosis. The contribution of molecular-level analysis to cancer chemotherapy., Cancer chemotherapy and pharmacology, 50(5), 2002
  28. Current status of the molecular mechanisms of anticancer drug-induced apoptosis. The contribution of molecular-level analysis to cancer chemotherapy., Cancer chemotherapy and pharmacology, 50(5), 2002
  29. Inducing cancer cell death by targeting transcription factors., Anti-cancer drugs, 14(1), 2003
  30. Inducing cancer cell death by targeting transcription factors., Anti-cancer drugs, 14(1), 2003
  31. Inducing cancer cell death by targeting transcription factors., Anti-cancer drugs, 14(1), 2003
  32. Antisense Bcl-2 and HER-2 oligonucleotide treatment of breast cancer cells enhances their sensitivity to anticancer drugs., International journal of oncology, 22(4), 2003
  33. Antisense Bcl-2 and HER-2 oligonucleotide treatment of breast cancer cells enhances their sensitivity to anticancer drugs., International journal of oncology, 22(4), 2003
  34. Antisense Bcl-2 and HER-2 oligonucleotide treatment of breast cancer cells enhances their sensitivity to anticancer drugs., International journal of oncology, 22(4), 2003
  35. Effect of Bcl-2 antisense oligonucleotide on drug-sensitivity in association with apoptosis in undifferentiated thyroid carcinoma., International journal of molecular medicine, 11(6), 2003
  36. Effect of Bcl-2 antisense oligonucleotide on drug-sensitivity in association with apoptosis in undifferentiated thyroid carcinoma., International journal of molecular medicine, 11(6), 2003
  37. Effect of Bcl-2 antisense oligonucleotide on drug-sensitivity in association with apoptosis in undifferentiated thyroid carcinoma., International journal of molecular medicine, 11(6), 2003
  38. Death receptor-dependent and -independent pathways in anticancer drug-induced apoptosis of breast cancer cells., Oncology reports, 10(6)
  39. Death receptor-dependent and -independent pathways in anticancer drug-induced apoptosis of breast cancer cells., Oncology reports, 10(6)
  40. Death receptor-dependent and -independent pathways in anticancer drug-induced apoptosis of breast cancer cells., Oncology reports, 10(6)
  41. Potential roles of antisense therapy in the molecular targeting of genes involved in cancer (review)., International journal of oncology, 24(1), 2004
  42. Potential roles of antisense therapy in the molecular targeting of genes involved in cancer (review)., International journal of oncology, 24(1), 2004
  43. Potential roles of antisense therapy in the molecular targeting of genes involved in cancer (review)., International journal of oncology, 24(1), 2004
  44. The role of Fas ligand and transforming growth factor beta in tumor progression: molecular mechanisms of immune privilege via Fas-mediated apoptosis and potential targets for cancer therapy., Cancer, 100(11), 2004
  45. The role of Fas ligand and transforming growth factor beta in tumor progression: molecular mechanisms of immune privilege via Fas-mediated apoptosis and potential targets for cancer therapy., Cancer, 100(11), 2004
  46. The role of Fas ligand and transforming growth factor beta in tumor progression: molecular mechanisms of immune privilege via Fas-mediated apoptosis and potential targets for cancer therapy., Cancer, 100(11), 2004
  47. Therapeutic potential of antisense Bcl-2 as a chemosensitizer for cancer therapy., Cancer, 101(11), 2004
  48. Therapeutic potential of antisense Bcl-2 as a chemosensitizer for cancer therapy., Cancer, 101(11), 2004
  49. Therapeutic potential of antisense Bcl-2 as a chemosensitizer for cancer therapy., Cancer, 101(11), 2004
  50. Rationale for sequential tamoxifen and anticancer drugs in adjuvant setting for patients with node- and receptor-positive breast cancer., International journal of oncology, 26(4), 2005
  51. Rationale for sequential tamoxifen and anticancer drugs in adjuvant setting for patients with node- and receptor-positive breast cancer., International journal of oncology, 26(4), 2005
  52. Rationale for sequential tamoxifen and anticancer drugs in adjuvant setting for patients with node- and receptor-positive breast cancer., International journal of oncology, 26(4), 2005
  53. Modulation of tamoxifen sensitivity by antisense Bcl-2 and trastuzumab in breast carcinoma cells., Cancer, 103(10), 2005
  54. Modulation of tamoxifen sensitivity by antisense Bcl-2 and trastuzumab in breast carcinoma cells., Cancer, 103(10), 2005
  55. Modulation of tamoxifen sensitivity by antisense Bcl-2 and trastuzumab in breast carcinoma cells., Cancer, 103(10), 2005
  56. Anterior resection of rectal cancer through a one hand-size incision with or without laparoscopy: proposal of one hand-size incision surgery (OHaSIS)., The Journal of surgical research, 129(1), 2005
  57. Anterior resection of rectal cancer through a one hand-size incision with or without laparoscopy: proposal of one hand-size incision surgery (OHaSIS)., The Journal of surgical research, 129(1), 2005
  58. Anterior resection of rectal cancer through a one hand-size incision with or without laparoscopy: proposal of one hand-size incision surgery (OHaSIS)., The Journal of surgical research, 129(1), 2005
  59. Caspase-dependent and -independent cell death pathways after DNA damage (Review)., Oncology reports, 14(3), 2005
  60. Caspase-dependent and -independent cell death pathways after DNA damage (Review)., Oncology reports, 14(3), 2005
  61. Caspase-dependent and -independent cell death pathways after DNA damage (Review)., Oncology reports, 14(3), 2005
  62. Role of mitochondria as the gardens of cell death., Cancer chemotherapy and pharmacology, 57(5), 2006
  63. Role of mitochondria as the gardens of cell death., Cancer chemotherapy and pharmacology, 57(5), 2006
  64. Role of mitochondria as the gardens of cell death., Cancer chemotherapy and pharmacology, 57(5), 2006
  65. Cancer cell immune escape and tumor progression by exploitation of anti-inflammatory and pro-inflammatory responses., Cancer biology & therapy, 4(9), 2005
  66. Cancer cell immune escape and tumor progression by exploitation of anti-inflammatory and pro-inflammatory responses., Cancer biology & therapy, 4(9), 2005
  67. Cancer cell immune escape and tumor progression by exploitation of anti-inflammatory and pro-inflammatory responses., Cancer biology & therapy, 4(9), 2005
  68. Neoadjuvant therapy of rectal cancer using oral tegaful-uracil (UFT) plus concomitant radiotherapy--a case report., Hiroshima journal of medical sciences, 54(3), 2005
  69. Neoadjuvant therapy of rectal cancer using oral tegaful-uracil (UFT) plus concomitant radiotherapy--a case report., Hiroshima journal of medical sciences, 54(3), 2005
  70. Neoadjuvant therapy of rectal cancer using oral tegaful-uracil (UFT) plus concomitant radiotherapy--a case report., Hiroshima journal of medical sciences, 54(3), 2005
  71. [Therapeutic potential of antisense (AS) Bcl-2 as a chemosensitizer for patients with gastric and breast carcinoma]., Gan to kagaku ryoho. Cancer & chemotherapy, 32(11), 2005
  72. [Therapeutic potential of antisense (AS) Bcl-2 as a chemosensitizer for patients with gastric and breast carcinoma]., Gan to kagaku ryoho. Cancer & chemotherapy, 32(11), 2005
  73. [Therapeutic potential of antisense (AS) Bcl-2 as a chemosensitizer for patients with gastric and breast carcinoma]., Gan to kagaku ryoho. Cancer & chemotherapy, 32(11), 2005
  74. A phase I trial of CPT-11 in combination with 5-fluorouracil plus leucovorin chemotherapy for patients with metastatic colorectal cancer., Hepato-gastroenterology, 53(68)
  75. A phase I trial of CPT-11 in combination with 5-fluorouracil plus leucovorin chemotherapy for patients with metastatic colorectal cancer., Hepato-gastroenterology, 53(68)
  76. A phase I trial of CPT-11 in combination with 5-fluorouracil plus leucovorin chemotherapy for patients with metastatic colorectal cancer., Hepato-gastroenterology, 53(68)
  77. Tumor-driven evolution of immunosuppressive networks during malignant progression., Cancer research, 66(11), 2006
  78. Tumor-driven evolution of immunosuppressive networks during malignant progression., Cancer research, 66(11), 2006
  79. Tumor-driven evolution of immunosuppressive networks during malignant progression., Cancer research, 66(11), 2006
  80. Phase I study of docetaxel (TXT) and 5-fluorouracil (5-FU) with concurrent radiotherapy in patients with advanced esophageal cancer., Anticancer research, 27(4C)
  81. Phase I study of docetaxel (TXT) and 5-fluorouracil (5-FU) with concurrent radiotherapy in patients with advanced esophageal cancer., Anticancer research, 27(4C)
  82. Phase I study of docetaxel (TXT) and 5-fluorouracil (5-FU) with concurrent radiotherapy in patients with advanced esophageal cancer., Anticancer research, 27(4C)
  83. [Adjuvant surgery for advanced gastric cancer]., Gan to kagaku ryoho. Cancer & chemotherapy, 37(2), 2010
  84. [Adjuvant surgery for advanced gastric cancer]., Gan to kagaku ryoho. Cancer & chemotherapy, 37(2), 2010
  85. [Adjuvant surgery for advanced gastric cancer]., Gan to kagaku ryoho. Cancer & chemotherapy, 37(2), 2010
  86. Advanced esophageal cancer with situs inversus totalis successfully treated with chemoradiotherapy followed by esophagectomy: case report., Hiroshima journal of medical sciences, 60(1), 2011
  87. Advanced esophageal cancer with situs inversus totalis successfully treated with chemoradiotherapy followed by esophagectomy: case report., Hiroshima journal of medical sciences, 60(1), 2011
  88. Advanced esophageal cancer with situs inversus totalis successfully treated with chemoradiotherapy followed by esophagectomy: case report., Hiroshima journal of medical sciences, 60(1), 2011
  89. Airway stenting for malignant respiratory complications in esophageal cancer., Anticancer research, 32(5), 2012
  90. Airway stenting for malignant respiratory complications in esophageal cancer., Anticancer research, 32(5), 2012
  91. Airway stenting for malignant respiratory complications in esophageal cancer., Anticancer research, 32(5), 2012
  92. Leiomyosarcoma of the sigmoid colon with multiple liver metastases and gastric cancer: a case report., BMC gastroenterology, 12, 2012
  93. Leiomyosarcoma of the sigmoid colon with multiple liver metastases and gastric cancer: a case report., BMC gastroenterology, 12, 2012
  94. Leiomyosarcoma of the sigmoid colon with multiple liver metastases and gastric cancer: a case report., BMC gastroenterology, 12, 2012
  95. Treatment outcomes and prognostic factors for thoracic esophageal cancer with clinical evidence of adjacent organ invasion., Anticancer research, 33(8), 2013
  96. Treatment outcomes and prognostic factors for thoracic esophageal cancer with clinical evidence of adjacent organ invasion., Anticancer research, 33(8), 2013
  97. Treatment outcomes and prognostic factors for thoracic esophageal cancer with clinical evidence of adjacent organ invasion., Anticancer research, 33(8), 2013
  98. Ability of Blood Cell Parameters to Predict Clinical Outcomes of Nivolumab Monotherapy in Advanced Esophageal Squamous Cell Carcinoma, ONCOTARGETS AND THERAPY, 16, 263-273, 2023
  99. Real-world clinical outcomes of nivolumab and taxane as a second- or later-line therapy for recurrent or unresectable advanced esophageal squamous cell carcinoma, FRONTIERS IN ONCOLOGY, 13, 20230417
  100. Long-term results of chemoradiotherapy with elective nodal irradiation for resectable locally advanced esophageal cancer in three-dimensional planning system, INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 28(3), 382-391, 202303
  101. Blood biomarkers as predictors of pathological lymph node metastasis in clinical stage T1N0 esophageal squamous cell carcinoma, DISEASES OF THE ESOPHAGUS, 36(1), 20221231
  102. Correlation Between Tumor Uptake on FDG-PET and Malignant Features in Esophageal Squamous Cell Carcinoma After Neoadjuvant Chemotherapy Followed by Surgery, ANTICANCER RESEARCH, 42(12), 6037-6045, 202212
  103. Prognostic Factors for Patients With Esophageal Squamous Cell Carcinoma After Neoadjuvant Chemotherapy Followed by Surgery, IN VIVO, 36(6), 2852-2860, 2022
  104. Prognostic value of quantitative parameters for esophageal squamous cell carcinoma determined by preoperative FDG-PET after trimodal therapy, SURGERY, 172(2), 584-592, 202208
  105. Evaluation of Neoadjuvant Chemoradiotherapy Followed by Surgery for Borderline Resectable Esophageal Squamous Cell Carcinoma, WORLD JOURNAL OF SURGERY, 46(8), 1934-1943, 202208
  106. Clinical Outcomes of Esophagectomy and Chemoradiotherapy After Endoscopic Resection for Superficial Esophageal Squamous Cell Carcinoma, ANTICANCER RESEARCH, 42(5), 2791-2795, 202205
  107. Recurrent esophageal adenocarcinoma derived from ectopic gastric mucosa: A case report, THORACIC CANCER, 13(6), 876-879, 202203
  108. Neutrophil-to-Lymphocyte Ratio as a Predictor of Postoperative Recurrence and Prognosis in Oesophageal Squamous Cell Carcinoma, ANTICANCER RESEARCH, 42(3), 1499-1507, 202203
  109. ★, Clinicopathologic Features of Submucosal Esophageal Squamous Cell Carcinoma., Annals of Thoracic Surgery, 104(6), 1858-1864, 201712
  110. Cancer immunosuppression and autoimmune disease: beyond immunosuppressive networks for tumour immunity, IMMUNOLOGY, 119(2), 254-264, 2006
  111. The role of apoptosis in cancer cell survival and therapeutic outcome, CANCER BIOLOGY & THERAPY, 5(11), 1429-1442, 2006
  112. Potential functional role of plasmacytoid dendritic cells in cancer immunity, IMMUNOLOGY, 121(2), 149-157, 2007
  113. Phase I trial of oxaliplatin plus S-1 chemotherapy in patients with metastatic colorectal cancer., Oncology letters, 1(1), 95-98, 2010
  114. Neoadjuvant chemoradiotherapy with docetaxel, cisplatin, and 5-fluorouracil for esophageal cancer., Cancer chemotherapy and pharmacology, 69(6), 1499-1505, 2012
  115. Immunobiology of the sentinel lymph node and its potential role for antitumour immunity, LANCET ONCOLOGY, 7(12), 1006-1016, 2006
  116. Cancer immunoediting from immune surveillance to immune escape, IMMUNOLOGY, 121(1), 1-14, 2007
  117. A CASE OF ESOPHAGEAL CANCER WITH DERMATOMYOSITIS, The journal of the Japanese Practical Surgeon Society, 67(7), 1546-1549, 2006
  118. A CASE OF GIST OF DUODENUM SUCCESSFULLY TREATED WITH NEOADJUVANT IMATINIB AND LIMITED SURGERY, The journal of the Japanese Practical Surgeon Society, 68(9), 2248-2252, 2007
  119. Preclinical evaluation of antisense bcl-2 as a chemosensitizer for patients with gastric carcinoma., Cancer, 101(10), 2004
  120. Chemosensitization by STI571 targeting the platelet-derived growth factor/platelet-derived growth factor receptor-signaling pathway in the tumor progression and angiogenesis of gastric carcinoma., Cancer, 103(9), 2005
  121. Targeted therapy against Bcl-2-related proteins in breast cancer cells., Breast cancer research : BCR, 7(6), 2005
  122. A CASE OF ASYMPTOMATIC TRAUMATIC RIGHT DIAPHRAGMATIC HERNIA WITH DISLOCATION OF THE WHOLE LIVER AND RIGHT HEMICOLON, The journal of the Japanese Practical Surgeon Society, 68(3), 570-573, 2007
  123. Clinical Significance of FDG-PET to Predict Pathologic Tumor Invasion and Lymph Node Metastasis of Superficial Esophageal Squamous Cell Carcinoma, ANNALS OF SURGICAL ONCOLOGY, 23(12), 4086-4092, 201611
  124. Ability of Fluorine-18 Fluorodeoxyglucose Positron Emission Tomography to Predict Outcomes of Neoadjuvant Chemoradiotherapy Followed by Surgical Treatment for Esophageal Squamous Cell Carcinoma, ANNALS OF THORACIC SURGERY, 102(4), 1132-1140, 201610
  125. Role of definitive chemoradiotherapy using docetaxel and 5-fluorouracil in patients with unresectable locally advanced esophageal squamous cell carcinoma: a phase II study, DISEASES OF THE ESOPHAGUS, 29(8), 1115-1120, 2016
  126. Role of Postoperative C-Reactive Protein Levels in Predicting Prognosis After Surgical Treatment of Esophageal Cancer, WORLD JOURNAL OF SURGERY, 41(6), 1558-1565, 201706
  127. Effects of Neoadjuvant Chemoradiotherapy on Pathological TNM Stage and Their Prognostic Significance for Surgically-treated Esophageal Squamous Cell Carcinoma, ANTICANCER RESEARCH, 37(10), 5639-5646, 201710
  128. Clinicopathologic Features of Submucosal Esophageal Squamous Cell Carcinoma, ANNALS OF THORACIC SURGERY, 104(6), 1858-1864, 201712
  129. Evaluation of Prognostic Factors for Esophageal Squamous Cell Carcinoma Treated with Neoadjuvant Chemoradiotherapy Followed by Surgery, WORLD JOURNAL OF SURGERY, 42(5), 1496-1505, 201805
  130. Treatment Outcomes and Prognostic Factors After Recurrence of Esophageal Squamous Cell carcinoma, WORLD JOURNAL OF SURGERY, 42(7), 2190-2198, 201807
  131. Preoperative prediction of a pathologic complete response of esophageal squamous cell carcinoma to neoadjuvant chemoradiotherapy, SURGERY, 164(1), 40-48, 201807
  132. Impact of Interval Between Neoadjuvant Chemoradiation and Surgery Upon Morbidity and Survival of Patients with Squamous Cell Carcinoma of Thoracic Esophagus, ANTICANCER RESEARCH, 38(9), 5239-5245, 201809
  133. Long-term results of neoadjuvant chemoradiotherapy using cisplatin and 5-fluorouracil followed by esophagectomy for resectable, locally advanced esophageal squamous cell carcinoma, JOURNAL OF RADIATION RESEARCH, 59(5), 616-624, 201809
  134. Early Recurrence and Cancer Death After Trimodal Therapy for Esophageal Squamous Cell Carcinoma, ANTICANCER RESEARCH, 39(3), 1433-1440, 201903
  135. Clinical Significance of F-18-Fluorodeoxyglucose-Positron Emission Tomography-Positive Lymph Nodes to Outcomes of Trimodal Therapy for Esophageal Squamous Cell Carcinoma, ANNALS OF SURGICAL ONCOLOGY, 26(6), 1869-1878, 201906
  136. Traditional Japanese herbal medicine rikkunshito increases food intake and plasma acylated ghrelin levels in patients with esophageal cancer treated by cisplatin-based chemotherapy, JOURNAL OF THORACIC DISEASE, 11(6), 2470-2478, 201906
  137. Long-term Esophageal Cancer Survivor Treated by Bypass for Esophagobronchial Fistula After Chemoradiotherapy: A Case Report, ANTICANCER RESEARCH, 39(8), 4399-4403, 201908
  138. A case of primary malignant melanoma of the esophagus with a widely expanded surface area, CLINICAL JOURNAL OF GASTROENTEROLOGY, 12(5), 424-428, 201910
  139. Thoracoscopic double-flap reconstruction for esophagogastric junction cancer: A case report, INTERNATIONAL JOURNAL OF SURGERY CASE REPORTS, 67, 102-105, 2020
  140. Tumor Response in Esophageal Squamous Cell Carcinoma Treated With Neoadjuvant Chemotherapy Followed by Surgery, ANTICANCER RESEARCH, 40(2), 1153-1160, 202002
  141. Circulating microRNA/isomiRs as novel biomarkers of esophageal squamous cell carcinoma, PLOS ONE, 15(4), 20200406
  142. Risk Factors for Recurrence in Esophageal Squamous Cell Carcinoma Without Pathological Complete Response After Trimodal Therapy, ANTICANCER RESEARCH, 40(8), 4387-4394, 202008
  143. Successful Management of Esophageal Cancer With Perforation Using Bypass Surgery Followed by Definitive Chemoradiotherapy, IN VIVO, 34(4), 2169-2172, 2020
  144. Predictions of Pathological Features and Recurrence Based on FDG-PET Findings of Esophageal Squamous Cell Carcinoma after Trimodal Therapy, ANNALS OF SURGICAL ONCOLOGY, 27(11), 4422-4430, 202010
  145. Long-term results of definitive chemoradiotherapy for unresectable locally advanced esophageal squamous cell carcinoma, JOURNAL OF RADIATION RESEARCH, 62(1), 142-148, 202101
  146. Distribution of Lymph Node Metastasis in Esophageal Squamous Cell Carcinoma After Trimodal Therapy, ANNALS OF SURGICAL ONCOLOGY, 28(3), 1798-1807, 202103
  147. Comparison of Open and Thoracoscopic Esophagectomy in Patients With Locally Advanced Esophageal Squamous Cell Carcinoma After Neoadjuvant Therapy, ANTICANCER RESEARCH, 41(6), 3011-3021, 202106
  148. Long-term results of definitive chemoradiotherapy for unresectable locally advanced esophageal squamous cell carcinoma, Journal of radiation research, 62(1), 142-148, 20210101
  149. Distribution of Lymph Node Metastasis in Esophageal Squamous Cell Carcinoma After Trimodal Therapy, Annals of surgical oncology, 28(3), 1798-1807, 20200903
  150. Prediction of the tumor response and survival based on computed tomography in esophageal squamous cell carcinoma after trimodality therapy, Surgery Today, 51(9), 1496-1505, 20210402
  151. Comparison of Open and Thoracoscopic Esophagectomy in Patients With Locally Advanced Esophageal Squamous Cell Carcinoma After Neoadjuvant Therapy, Anticancer Research, 41(6), 3011-3021, 20210313
  152. Prediction of the tumor response and survival based on computed tomography in esophageal squamous cell carcinoma after trimodality therapy, SURGERY TODAY, 51(9), 1496-1505, 202109
  153. Prospective Randomized Trial of Early Postoperative Enteral and Total Parenteral Nutrition for Treating Esophageal Cancer, ANTICANCER RESEARCH, 41(12), 6237-6246, 202112

Awards

  1. 2012/10/16, Best abstract oral presentation, International Society for Diseases of the Esophagus